EMA Committee Recommends Approval of Sarclisa-VRd Induction in Newly Diagnosed Multiple Myeloma Patients Eligible for Transplant

Sarclisa recommended for EU approval in newly diagnosed multiple myeloma - Pharmafile

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s Sarclisa (isatuximab) for approval in combination with bortezomib, lenalidomide and dexamethasone (VRd) for induction treatment in adults with newly diagnosed multiple myeloma (NDMM) eligible for stem cell transplant. If approved, this would mark Sarclisa’s fourth indication in the EU and […] The post Sarclisa recommended for EU approva…

CEPHEUS Trial: MRD Negativity

Panelists discuss updated American Society of Clinical Oncology (ASCO) data showing that adding a CD38 monoclonal antibody to frontline triplet therapy improves minimal residual disease (MRD) negativity and progression-free survival in standard and intermediate-risk multiple myeloma, while reinforcing the need for tailored strategies in high-risk patients.

EMA Committee Recommends Approval of Sarclisa-VRd Induction in Newly Diagnosed Multiple Myeloma Patients Eligible for Transplant

Open the article to view the coverage from EuropaWire.eu